RecruitingPhase 1

A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities

Lead sponsor

Viking Therapeutics, Inc.

Asset

VK2735

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

Estimated enrollment

270

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoint

•Evaluate the Safety and Tolerability VK2735

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07838740

Org study IDVK2735-102

Timeline

Milestones

Study start2025-11-18actual

Study first posted2026-09-24actual

Last update posted2026-09-24actual

Primary completion2027-05estimated (month precision)

Study completion2027-07estimated (month precision)

Assets

Investigational agents

VK2735

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age60 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Must be capable of giving a signed informed consent form (ICF).

•Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.

•BMI ≥ 30 kg/m2.

•Willing to comply with contraceptive requirements.

Exclusion criteria

•Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history, or laboratory testing, as assessed by the Investigator.

•Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion or drug absorption.

•Any condition that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator.

•History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.

•Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).

•Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).

•Alanine aminotransferase (ALT) level or aspartate transaminase (AST) level > 3.0 times the ULN for the reference range.

•Impaired renal function with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 as measured at Screening.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Evaluate the Safety and Tolerability VK2735

Time frame:33 weeks

descriptive

Secondary/protocol endpoint

Evaluate the Pharmacokinetic profile of VK23735

Time frame:38 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.